BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $520,500 | +94.1% | 73,517 | +93.0% | 0.00% | 0.0% |
| Q2 2023 | $268,140 | -17.4% | 38,088 | -2.1% | 0.00% | 0.0% |
| Q1 2023 | $324,493 | +13.1% | 38,908 | +55.7% | 0.00% | 0.0% |
| Q4 2022 | $286,908 | +1.0% | 24,992 | +10.8% | 0.00% | 0.0% |
| Q3 2022 | $284,000 | -10.4% | 22,560 | -24.6% | 0.00% | 0.0% |
| Q2 2022 | $317,000 | -65.6% | 29,917 | -47.2% | 0.00% | -50.0% |
| Q1 2022 | $922,000 | -32.7% | 56,679 | -42.7% | 0.00% | 0.0% |
| Q4 2021 | $1,369,000 | -26.8% | 98,864 | -24.0% | 0.00% | -33.3% |
| Q3 2021 | $1,869,000 | +9.6% | 130,073 | +20.5% | 0.00% | 0.0% |
| Q2 2021 | $1,706,000 | +173.4% | 107,921 | +75.8% | 0.00% | +200.0% |
| Q1 2021 | $624,000 | +34.5% | 61,386 | -1.5% | 0.00% | 0.0% |
| Q4 2020 | $464,000 | +30.3% | 62,346 | -39.9% | 0.00% | 0.0% |
| Q3 2020 | $356,000 | -37.0% | 103,777 | -12.5% | 0.00% | 0.0% |
| Q2 2020 | $565,000 | +1245.2% | 118,613 | +468.4% | 0.00% | – |
| Q1 2020 | $42,000 | -74.4% | 20,869 | -56.2% | 0.00% | – |
| Q4 2019 | $164,000 | +118.7% | 47,649 | +81.5% | 0.00% | – |
| Q3 2019 | $75,000 | -54.3% | 26,257 | -39.3% | 0.00% | – |
| Q2 2019 | $164,000 | -57.1% | 43,277 | -7.7% | 0.00% | – |
| Q1 2019 | $382,000 | +5.8% | 46,870 | +4.9% | 0.00% | – |
| Q4 2018 | $361,000 | +159.7% | 44,685 | +53.9% | 0.00% | – |
| Q1 2018 | $139,000 | -46.7% | 29,043 | -45.3% | 0.00% | – |
| Q4 2017 | $261,000 | -24.6% | 53,140 | -19.6% | 0.00% | – |
| Q3 2017 | $346,000 | +14.6% | 66,119 | +21.7% | 0.00% | – |
| Q2 2017 | $302,000 | -14.0% | 54,322 | +30.1% | 0.00% | – |
| Q1 2017 | $351,000 | +26.3% | 41,751 | -57.3% | 0.00% | – |
| Q2 2016 | $278,000 | -21.2% | 97,873 | -21.5% | 0.00% | -100.0% |
| Q1 2016 | $353,000 | +39.0% | 124,614 | +407.3% | 0.00% | – |
| Q4 2015 | $254,000 | -58.6% | 24,564 | -54.4% | 0.00% | -100.0% |
| Q3 2015 | $614,000 | +86.6% | 53,816 | +144.0% | 0.00% | 0.0% |
| Q2 2015 | $329,000 | -84.1% | 22,056 | -90.4% | 0.00% | -80.0% |
| Q1 2015 | $2,064,000 | -64.3% | 228,635 | -51.9% | 0.01% | -58.3% |
| Q4 2014 | $5,782,000 | +72.3% | 475,435 | +38.6% | 0.01% | +33.3% |
| Q3 2014 | $3,355,000 | +133.1% | 343,062 | +204.0% | 0.01% | +125.0% |
| Q2 2014 | $1,439,000 | +21.7% | 112,862 | +1.0% | 0.00% | 0.0% |
| Q1 2014 | $1,182,000 | +63.3% | 111,762 | +17.3% | 0.00% | +100.0% |
| Q4 2013 | $724,000 | – | 95,262 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 3,926,700 | $56,427,000 | 4.43% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $27,601,000 | 3.44% |
| HealthCor Management, L.P. | 3,849,470 | $55,317,000 | 2.39% |
| MPM BioImpact LLC | 704,767 | $10,128,000 | 1.57% |
| Baker Brothers Advisors | 12,710,818 | $182,654,000 | 0.80% |
| Bain Capital Public Equity Management II, LLC | 1,472,471 | $21,159,000 | 0.74% |
| Biondo Investment Advisors, LLC | 267,480 | $3,844,000 | 0.66% |
| North Star Investment Management Corp. | 442,900 | $6,364,000 | 0.52% |
| DOLIVER ADVISORS, LP | 100,000 | $1,437,000 | 0.48% |
| Lisanti Capital Growth, LLC | 219,450 | $3,153,000 | 0.46% |